GeoVax Labs Inc/$GOVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GeoVax Labs Inc
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Ticker
$GOVX
Sector
Primary listing
Employees
19
Headquarters
Website
GeoVax Labs Inc Metrics
BasicAdvanced
$3.4m
-
-$15.94
-
-
Price and volume
Market cap
$3.4m
52-week high
$4.40
52-week low
$0.96
Average daily volume
10m
Financial strength
Current ratio
1.061
Quick ratio
0.555
Long term debt to equity
39.918
Total debt to equity
79.91
Profitability
EBITDA (TTM)
-21.443
Gross margin (TTM)
-2,026.23%
Net profit margin (TTM)
-2,507.27%
Operating margin (TTM)
-2,523.38%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-194.58%
Return on equity (TTM)
-509.28%
Valuation
Price to revenue (TTM)
1.857
Price to book
6.74
Price to tangible book (TTM)
6.74
Price to free cash flow (TTM)
-0.083
Free cash flow yield (TTM)
-1,204.38%
Free cash flow per share (TTM)
-14.212
Growth
Revenue change (TTM)
-84.76%
Earnings per share change (TTM)
-80.27%
10-year revenue growth (CAGR)
8.64%
3-year earnings per share growth (CAGR)
-61.02%
GeoVax Labs Inc News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs